We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Precision Medicine Institute
Colleague Insights
Video Expert Opinion
Resource Library
Conferences
Tumor Boards
Sign in
Join now
featured
Published in Lung Cancer

Expert Opinion / Cases · May 18, 2021

Advanced NSCLC: Anti-PD-1 Rechallenge After Immune-Related Toxicity

Written by
Michael J. Grant MD

 

 Save  Recommend
 Share

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • GALA NAUSICAA  ROMERO MORATALLA

    Nov 18, 2021

    subsequent-line chemotherapy +/- anti-VEGF
autoinmune disease such as rheumatoid arthritis
anti PDL-1 produce autoinmune toxicity in several location,por example in lung,myocardial,renal,liver amon others

  • Jul 04, 2022

    Pending Moderator approval.
    Delete

Further Reading

Most Read This Week

Recently Updated